TriSalus Life Sciences Net Profit Margin 2021-2024 | TLSI
TriSalus Life Sciences net profit margin from 2021 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
| TriSalus Life Sciences Net Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Net Income | Net Margin |
| 2024-12-31 | $0.03B | $-0.03B | -117.86% |
| 2024-09-30 | $0.03B | $-0.06B | -223.08% |
| 2024-06-30 | $0.02B | $-0.06B | -237.50% |
| 2024-03-31 | $0.02B | $-0.07B | -309.09% |
| 2023-12-31 | $0.02B | $-0.06B | -331.58% |
| 2023-09-30 | $0.02B | $-0.07B | -352.38% |
| 2023-06-30 | $0.02B | $-0.08B | -400.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $0.165B | $0.029B |
| TriSalus Life Sciences Inc. is an oncology company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors. TriSalus Life Sciences Inc., formerly known as MedTech Acquisition Corporation, is based in CHICAGO. | |||